open access

Vol 1, No 2 (2005)
Review paper
Published online: 2005-06-08
Get Citation

Mantle cell lymphoma - novel therapeutic options

Katarzyna Domańska-Czyż
Onkol. Prak. Klin 2005;1(2):96-108.

open access

Vol 1, No 2 (2005)
REVIEW ARTICLES
Published online: 2005-06-08

Abstract

Mantle cell lymphoma is associated with the worst prognosis among malignant lymphomas. Standard chemotherapy is not effective and median survival of 5 years is about 25%. Intensified induction regimens lead to higher initial response rate, but the overall survival is unchanged.
Induction chemotherapy combined with rituximab may prolong time to progression and overall survival. High dose chemotherapy followed by autologous stem cell transplantation in first remission is associated with the best disease free and overall survival reported to date. Among available treatment options high dose chemotherapy should be considered standard approach in young patients. However its definite role should be confirmed in randomized clinical trials. In addition the role of molecular remission and maintenance therapy with monoclonal antibodies should be established.

Abstract

Mantle cell lymphoma is associated with the worst prognosis among malignant lymphomas. Standard chemotherapy is not effective and median survival of 5 years is about 25%. Intensified induction regimens lead to higher initial response rate, but the overall survival is unchanged.
Induction chemotherapy combined with rituximab may prolong time to progression and overall survival. High dose chemotherapy followed by autologous stem cell transplantation in first remission is associated with the best disease free and overall survival reported to date. Among available treatment options high dose chemotherapy should be considered standard approach in young patients. However its definite role should be confirmed in randomized clinical trials. In addition the role of molecular remission and maintenance therapy with monoclonal antibodies should be established.
Get Citation

Keywords

mantle cell lymphoma; induction chemotherapy; high-dose chemotherapy and stem cell transplantation; maintenance therapy; rituximab

About this article
Title

Mantle cell lymphoma - novel therapeutic options

Journal

Oncology in Clinical Practice

Issue

Vol 1, No 2 (2005)

Article type

Review paper

Pages

96-108

Published online

2005-06-08

Bibliographic record

Onkol. Prak. Klin 2005;1(2):96-108.

Keywords

mantle cell lymphoma
induction chemotherapy
high-dose chemotherapy and stem cell transplantation
maintenance therapy
rituximab

Authors

Katarzyna Domańska-Czyż

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl